about
Selective incorporation of polyanionic molecules into hamster prions.Formation of native prions from minimal components in vitroUltra-sensitive detection of prion protein fibrils by flow cytometry in blood from cattle affected with bovine spongiform encephalopathyGeneration of Aptamers with an Expanded Chemical RepertoireSmart functional nucleic acid chimeras: enabling tissue specific RNA targeting therapyUnique quadruplex structure and interaction of an RNA aptamer against bovine prion proteinAnti-prion activity of an RNA aptamer and its structural basisA visual dual-aptamer logic gate for sensitive discrimination of prion diseases-associated isoform with reusable magnetic microparticles and fluorescence quantum dotsRNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivityCharacterization of 2'-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion.Development of the anti-VEGF aptamer to a therapeutic agent for clinical ophthalmology.Glycosaminoglycan sulphation affects the seeded misfolding of a mutant prion proteinFluorescence-activated cell sorting for aptamer SELEX with cell mixtures.Prion diseases: from molecular biology to intervention strategies.Phosphorothioate oligonucleotides reduce PrP levels and prion infectivity in cultured cells.Recent advances in prion chemotherapeutics.Current progress of RNA aptamer-based therapeutics.Neurodegenerative diseases: quantitative predictions of protein-RNA interactions.Current and future molecular diagnostics for prion diseases.Cross-talk between prion protein and quadruplex-forming nucleic acids: a dynamic complex formation.Therapeutic approaches for prion disorders.Disease-specific motifs can be identified in circulating nucleic acids from live elk and cattle infected with transmissible spongiform encephalopathies.Anti-bovine prion protein RNA aptamer containing tandem GGA repeat interacts both with recombinant bovine prion protein and its beta isoform with high affinityRecent progress toward the templated synthesis and directed evolution of sequence-defined synthetic polymersA computationally designed DNA aptamer template with specific binding to phosphatidylserine.Modelling neurodegeneration in prion disease - applications for drug development.Small RNA drugs for prion disease: a new frontier.Unraveling Prion Protein Interactions with Aptamers and Other PrP-Binding Nucleic Acids.Anti-innexin 2 aptamers specifically inhibit the heterologous interaction of the innexin 2 and innexin 3 carboxyl-termini in vitro.G-quadruplexes within prion mRNA: the missing link in prion disease?Nucleic acid aptamers in cancer research, diagnosis and therapy.RNA aptamers selectively modulate protein recruitment to the cytoplasmic domain of beta-secretase BACE1 in vitro.Characterization and application of a novel RNA aptamer against the mouse prion protein.DNA aptamers that bind to PrP(C) and not PrP(Sc) show sequence and structure specificity.Polyetheylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo.Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer's disease.A DNA Spiegelmer to staphylococcal enterotoxin B.Aptamers and their applications in nanomedicine.Aptamer-Functionalized Nanoparticles as "Smart Bombs": The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment.A Highlight of Recent Advances in Aptamer Technology and Its Application.
P2860
Q24596538-D88C43FD-90B5-458D-91EB-591A6B263310Q24676353-6617227C-5B20-4394-BD12-584F246234ECQ24816040-A4E1B858-D5D0-4E75-8044-B41AD6B4F39DQ26782794-7CAF6360-1D6A-4899-8F95-7A59F2A2B298Q27025832-3CA05E1F-B9A6-40BB-BDD3-99A0BB7E325DQ27656952-21E265AF-7BA8-4742-9C09-341C1195488BQ27675235-942FB904-4EE0-4AAD-8A7A-369F897CC8A8Q28485974-B9F9EBE7-D572-4C22-AC69-59919CD92F67Q30879431-AB36C982-C792-463C-81FB-664F49115569Q31151988-8AB37482-68F2-47D5-B129-01A9551A8FF3Q33492343-A6BD1616-C931-4E79-BE33-B19D0CDCE2A5Q33680310-5A862C3E-B08D-44EA-BA4B-DC7CF36C3A7BQ33762078-0DD04CCB-8F40-4514-A06D-7780B1CEF2C7Q35602374-F303A60E-D64E-4AEE-91FD-DBB50AA28C25Q35844090-2CA449C1-7642-4FDA-B25E-AEF79F6150BEQ35944199-7BA921E3-500A-4A6A-9D93-4C7FDEEBB03DQ36365202-2B0C0D9F-B4FB-4A08-B8CD-42DB2E88B78FQ36526561-B364F6AE-2FA2-49B1-BF0E-58CE3145C4E9Q36528891-6D543C31-CD44-407F-8005-9931FF7E7708Q36668697-626F5DA8-73A7-4A1C-AC16-4AE60DC597A0Q36901944-E718CE92-A87D-4D48-BD99-2FD71A70B1EDQ37077421-B19F6DC4-F126-4DDB-AC0A-1E06CC2368F7Q37080546-E4AC4C6B-9F79-46AD-9A04-7E406B8A1A9BQ37218533-914E6F76-7A51-4C72-AD7C-67B76D3D07C9Q37403863-1C2F056D-CA3B-4C29-B3A9-61852F91DE29Q38089150-4F10AAFD-DC9E-4553-997D-884052308C1CQ38121120-0B586B03-F3B6-4A7C-8D61-830AF720256EQ38288126-EDC5AC5E-F4C7-405E-9673-04B8D29F76C2Q38301069-1C754B63-42A4-47B7-A106-F7B1B5DA41FFQ38305734-90126B69-8085-45D2-A2B8-F35059E4E167Q38308357-7DD43AB3-D0AC-4C4A-91CC-5B6698F96BB9Q38310913-C783A7C4-EB4B-4363-A561-9A719B28DF0DQ38314743-EC560189-0346-4B4B-B460-F78AA29644A0Q38316301-16FC1FF1-059A-4446-A6E1-192B687D10ADQ38339945-71E4F2AD-C7B6-4AA6-B568-A4959EF5E2E4Q38342641-4EB133DA-077F-49A7-8089-B977DC8B729CQ38353738-D4A3142D-FB80-43D8-A217-9E6DC36FD2A3Q38353973-982B7936-A25D-42AE-AD12-38C7F34D7F36Q38491805-FBFFF022-3AB9-420C-BF77-597865C85F52Q38541697-728D49C1-2168-401C-A5C6-1905F5FE0163
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Prion-protein-specific aptamer reduces PrPSc formation.
@en
type
label
Prion-protein-specific aptamer reduces PrPSc formation.
@en
prefLabel
Prion-protein-specific aptamer reduces PrPSc formation.
@en
P2093
P1433
P1476
Prion-protein-specific aptamer reduces PrPSc formation.
@en
P2093
Daniela Proske
Ernst-L Winnacker
Franziska Wopfner
Hermann M Schätzl
Michael Famulok
Sabine Gilch
P304
P356
10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C
P577
2002-08-01T00:00:00Z